Holen Sie sich die Stockscreener-App
164.97
1.67%
2.71
Vorhandelsmarkt:
164.94
-0.03
-0.02%
Jazz Pharmaceuticals Plc Aktie (JAZZ) Neueste Nachrichten
Piper Sandler Raises Price Target for Jazz Pharmaceuticals (JAZZ) to $219 | JAZZ Stock News - GuruFocus
Piper Sandler raises Jazz Pharmaceuticals stock price target to $219 on positive trial results - Investing.com UK
Carr Patricia, SVP at Jazz Pharma, sells $797k in JAZZ stock - Investing.com India
Jazz Pharmaceuticals Insider Sold Shares Worth $797,783, According to a Recent SEC Filing - marketscreener.com
Jazz Pharmaceuticals (Nasdaq: JAZZ) shares Phase 4 DUET Xywav data in narcolepsy, IH - Stock Titan
Kennedy Capital Management LLC Buys Shares of 10,367 Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals Plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking After Shares Rocket 29% - 富途牛牛
Schroder Investment Management Group Acquires 8,444 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Why Analysts Think Jazz Pharmaceuticals Story Is Changing After New Ziihera Growth Outlook - Yahoo Finance
Jazz Pharmaceuticals to present new Epidiolex data at epilepsy meeting By Investing.com - Investing.com Nigeria
Affinity Asset Advisors LLC Makes New $2.65 Million Investment in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Do New Epidiolex Real‑World Data Reframe Jazz Pharmaceuticals' (JAZZ) Neurology Growth Ambitions? - simplywall.st
VP Carr Files To Sell 4,660 Of Jazz Pharmaceuticals Plc [JAZZ] - TradingView
Jazz (JAZZ) Up 24.5% Since Last Earnings Report: Can It Continue? - sharewise.com
Jazz Pharmaceuticals plc to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex®? (Cannabidiol) Outcomes in Treatment-Resistant Epilepsies At the American Epilepsy Society 2025 Annual Meeting - marketscreener.com
Jazz Pharmaceuticals to present new Epidiolex data at epilepsy meeting - Investing.com
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting - PR Newswire
Saturn V Capital Management LP Buys New Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Trials, Sales Wins Sends Jazz Pharmaceuticals Higher - Yahoo Finance
Dir O'Keefe Surrenders 603 Of Jazz Pharmaceuticals Plc [JAZZ] - TradingView
Will Jazz Pharmaceuticals plc stock pay special dividendsEarnings Beat & High Conviction Buy Zone Picks - Newser
Jazz Pharmaceuticals PLC $JAZZ Shares Purchased by Systematic Financial Management LP - MarketBeat
Is Jazz Pharmaceuticals plc (J7Z) stock attractive for growth fundsEarnings Summary Report & Real-Time Buy Signal Alerts - Newser
Why hedge funds are buying Jazz Pharmaceuticals plc stock2025 Volume Leaders & Low Drawdown Momentum Trade Ideas - Newser
What MACD trends signal for Jazz Pharmaceuticals plc (J7Z) stockPortfolio Profit Report & Expert Verified Movement Alerts - Newser
How Jazz Pharmaceuticals plc (J7Z) stock performs in easing cyclesShort Setup & Weekly Market Pulse Updates - Newser
Mackenzie Financial Corp Raises Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals PLC $JAZZ Shares Bought by Prudential Financial Inc. - MarketBeat
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Distillate Capital Partners LLC - MarketBeat
Will Jazz Pharmaceuticals plc (J7Z) stock benefit from infrastructure billQuarterly Performance Summary & Fast Moving Market Watchlists - Newser
Will Jazz Pharmaceuticals plc (J7Z) stock outperform benchmarksQuarterly Risk Review & Expert Verified Movement Alerts - Newser
Why Jazz Pharmaceuticals plc (J7Z) stock appeals to dividend investorsPrice Action & AI Driven Stock Movement Reports - Newser
Does Jazz Pharmaceutical's Acquisition of Gentium S.p.A. Signal Investment Upside? - AOL.com
Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells $13,780,275.00 in Stock - MarketBeat
Jazz to present pivotal phase 3 results for Ziihera in GEA at ASCO GI - Investing.com Canada
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium - PR Newswire
Looking Into Jazz Pharmaceuticals PLC's Recent Short Interest - Benzinga
Capital Fund Management S.A. Takes $4.27 Million Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Loomis Sayles & Co. L P Trims Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Is Jazz Pharmaceuticals plc stock attractive for retirement portfoliosJuly 2025 Recap & Reliable Entry Point Trade Alerts - Newser
Why Jazz Pharmaceuticals plc (J7Z) stock remains stableJuly 2025 Momentum & Fast Gain Swing Alerts - Newser
Jazz Pharmaceuticals Insider Sold Shares Worth $13,780,337, According to a Recent SEC Filing - marketscreener.com
Dir O'Keefe Files To Sell 1,249 Of Jazz Pharmaceuticals Plc [JAZZ] - TradingView
Jazz Pharmaceuticals Director Bruce C. Cozadd Sells 77,500 Shares - TradingView
Chmn Cozadd Sells 77,500 ($13.8M) Of Jazz Pharmaceuticals Plc [JAZZ] - TradingView
Jazz Pharmaceuticals PLC $JAZZ Stake Boosted by Vinva Investment Management Ltd - MarketBeat
American Century Companies Inc. Has $26.85 Million Stake in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Legal & General Group Plc Purchases 18,675 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
SG Americas Securities LLC Has $377,000 Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals PLC $JAZZ Shares Bought by Measured Wealth Private Client Group LLC - MarketBeat
Insomnia Therapeutics Market is Going to Boom: Strategic - openPR.com
Jazz Pharmaceuticals PLC $JAZZ Shares Acquired by Ensign Peak Advisors Inc - MarketBeat
A Look at Jazz Pharmaceuticals’s Valuation After Breakthrough Phase 3 Ziihera Trial Results - Yahoo Finance
JPMorgan Chase & Co. Purchases 59,252 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Dynamic Technology Lab Private Ltd Sells 2,945 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals plc (JAZZ) Stock Forecasts - Yahoo Finance
The Bull Case For Jazz Pharmaceuticals (JAZZ) Could Change Following Breakthrough Phase 3 Ziihera Trial Results - simplywall.st
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):